drugset / Trial / NCT00325234

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

NCT00325234

Phase 2 Completed 135 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to help answer the following research questions: * whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast cancer to make the tumor smaller or disappear and for how long * to learn more about the side effects in each chemotherapy combination treatment arm * to assess how participants with advanced breast cancer report health changes while receiving any of the chemotherapy combination arm

Timeline

Start
2006-06
Primary completion
2010-04
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Comparator Gemcitabine Small molecule 1200 mg/m2 Intravenous
Subject Pemetrexed Small molecule 600 mg/m2 Intravenous
Comparator Vinorelbine Small molecule 30 mg/m2 Intravenous

Indications